Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
 & Lead Plaintiff Deadline: June 4, 2018 - EconoTimes)
NEW YORK, April 20, 2018 -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed Cancer Genetics, Inc. (“Cancer Genetics” or the “Company”) (NASDAQ:CGIX) and certain of its officers, on behalf of shareholders who purchased Cancer Genetics securities between March 23, 2017 and April 2, 2018, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/cgix.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Cancer Genetics had ineffective disclosure controls and internal controls over financial reporting; and (2) consequently, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/cgix or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Cancer Genetics you have until June 4, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
